PFOCUS.NS
Prime Focus Limited
NSEINREQUITY
Communication Services
DELAYED
Last price
300.15
▼ 7.65 (2.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
307.75
Prev close
307.80
Day high
309.50
Day low
298.50
Volume
684.15K
Market cap
$235.77B
P/E (TTM)
185.74
52W range
139.04 – 367.00
Day trading desk
Gap from prior close
-0.02%
Prior close 307.80
VWAP
303.38
-1.07% from price
Relative volume
0.89×
Normal
Session range
3.50%
298.50 – 308.95
Position in range
16%
Near session low
ATR (14D)
14.95
4.98% of price
Prior day high
314.60
PDH
Prior day low
296.00
PDL
Bid / ask spread
—
Quote not published
Session volume
680.17K
Avg 763.76K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+5.76%
+7.0%
1M
+5.21%
+1.9%
3M
+26.22%
+23.8%
6M
+13.78%
+1.9%
YTD
+28.52%
+16.6%
1Y
+82.13%
+62.0%
3Y
+184.81%
+109.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PFOCUS.NS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
667.11M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 23, 25 | A2R Holdings Promoter |
OTHER | 102.45M | $138.46M | Direct |
| Sep 23, 25 | Novator Capital Ltd. Institution- Corporation |
— | 14.32M | — | Direct |
| Sep 17, 25 | A2R Holdings Institution- Corporation |
OTHER | 159.54M | $218.23M | Direct |
| Sep 17, 25 | Novator Capital Ltd. Institution- Corporation |
— | 96.97M | — | Direct |
| Jun 27, 25 | A2R Holdings Promoter |
OTHER | 15.12M | — | Direct |
| Jun 27, 25 | A2R Holdings Promoter |
OTHER | 0 | — | Indirect |
| Jun 27, 25 | Malhotra (Naresh) Promoter |
OTHER | 15.12M | — | Direct |
| Jun 27, 25 | Malhotra (Naresh) Promoter |
OTHER | 0 | — | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
A2R Holdings |
Promoter | 413.07M | Other |
Malhotra (Naresh) |
Promoter | 43.56M | Other |
Novator Capital Ltd. |
Institution- Corporation | 111.28M | Other |
Fundamentals
Market cap$235.77B
Enterprise value$292.50B
Revenue (TTM)$49.19B
Gross profit$47.19B
EBITDA$15.74B
Net income$1.16B
EPS (TTM)$1.63
Free cash flow—
Total cash$9.24B
Total debt$57.17B
Book value / share$26.88
Shares outstanding778.77M
Float98.99M
Short % of float—
Dividend yield—
Beta (5Y)0.12
Valuation & profitability ratios
Trailing P/E185.74
Forward P/E43.13
PEG ratio—
Price / sales—
Price / book11.26
EV / revenue5.95
EV / EBITDA18.59
Gross margin95.92%
Operating margin9.66%
Profit margin2.35%
Return on equity—
Return on assets—
Debt / equity224.57
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $45.87B | $35.38B | $39.30B | $46.28B | — | +29.7% |
| Operating revenue | $45.87B | $35.38B | $39.30B | $46.28B | — | +29.7% |
| Cost of revenue | $3.03B | $1.88B | $3.52B | $3.34B | — | +61.4% |
| Gross profit | $42.84B | $33.50B | $35.78B | $42.94B | — | +27.9% |
| Selling, general & admin | — | $992.90M | $993.20M | $983.90M | $794.20M | — |
| Total operating expense | $35.19B | $30.69B | $38.16B | $37.81B | — | +14.6% |
| Operating income | $7.66B | $2.81B | -$2.38B | $5.13B | — | +172.8% |
| Net interest income | -$5.15B | -$5.38B | -$5.52B | -$4.16B | — | +4.3% |
| Pre-tax income | $3.34B | -$4.11B | -$5.87B | $3.06B | — | +181.4% |
| Tax provision | $328.58M | $475.49M | -$982.10M | $1.12B | — | -30.9% |
| Net income | $2.19B | -$3.77B | -$4.05B | $1.47B | — | +158.0% |
| Net income to common | $2.19B | -$3.77B | -$4.05B | $1.47B | — | +158.0% |
| Basic EPS | 3.94 | -12.57 | -13.50 | 6.49 | — | +131.3% |
| Diluted EPS | 3.92 | -12.57 | -13.50 | 6.38 | — | +131.2% |
| EBIT | $8.49B | $1.27B | -$288.05M | $7.01B | — | +567.4% |
| EBITDA | $15.06B | $6.32B | $4.42B | $11.67B | — | +138.2% |
| Basic shares | 555.22M | 300.01M | 299.58M | 299.54M | — | +85.1% |
| Diluted shares | 558.05M | 300.01M | 307.97M | 304.78M | — | +86.0% |
| Line item | 2026 | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.88B | $2.14B | $1.39B | $1.53B | — | +221.4% |
| Cash & short-term investments | $42.95B | $9.27B | $6.32B | $3.34B | — | +363.2% |
| Accounts receivable | $4.62B | $4.19B | $3.95B | $6.25B | — | +10.3% |
| Inventory | — | — | — | — | $0 | — |
| Total current assets | $50.65B | $33.43B | $31.15B | $23.32B | — | +51.5% |
| Property, plant & equipment | $13.51B | $13.19B | $14.26B | $15.59B | — | +2.4% |
| Goodwill & intangibles | $31.90B | $29.05B | $18.67B | $16.96B | — | +9.8% |
| Total assets | $106.49B | $85.26B | $71.27B | $67.84B | — | +24.9% |
| Total current liabilities | $72.42B | $50.11B | $23.37B | $16.53B | — | +44.5% |
| Current debt | $48.31B | $34.07B | $7.78B | $4.14B | — | +41.8% |
| Long-term debt | $1.10B | $6.86B | $31.52B | $34.72B | — | -84.0% |
| Total debt | $57.17B | $48.79B | $48.59B | $48.92B | — | +17.2% |
| Total liabilities | $81.04B | $64.82B | $63.51B | $66.27B | — | +25.0% |
| Retained earnings | — | -$12.65B | -$6.15B | -$8.98B | -$10.40B | — |
| Shareholder equity | $20.89B | $7.59B | $5.16B | $251.80M | — | +175.2% |
| Working capital | -$21.77B | -$16.68B | $7.78B | $6.79B | — | -30.5% |
| Net tangible assets | -$11.02B | -$21.46B | -$13.51B | -$16.71B | — | +48.7% |
| Shares issued | 775.99M | 299.99M | 299.85M | 299.54M | — | +158.7% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | $3.34B | -$4.11B | -$5.87B | $3.06B | +181.4% |
| Depreciation & amortisation | $6.58B | $5.05B | $4.98B | $4.67B | +30.1% |
| Stock-based compensation | $247.30M | $144.10M | $84.30M | $273.60M | +71.6% |
| Change in working capital | -$6.84B | -$5.77B | -$5.05B | -$7.92B | -18.6% |
| Operating cash flow | $10.24B | $2.99B | -$325.00M | $2.54B | +242.3% |
| Capital expenditure | -$5.32B | -$3.65B | -$3.05B | -$3.60B | -45.5% |
| Investing cash flow | -$5.90B | -$3.56B | -$3.17B | -$4.90B | -65.7% |
| Financing cash flow | $431.21M | $1.33B | $3.35B | $1.52B | -67.5% |
| Free cash flow | $4.92B | -$662.83M | -$3.38B | -$1.06B | +842.5% |
| End cash position | $6.88B | $2.14B | $1.39B | $1.53B | +221.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $12.56B | $13.75B | $11.92B | $10.43B | $9.77B | -8.7% |
| Operating revenue | $12.56B | $13.75B | $11.92B | $10.43B | $9.77B | -8.7% |
| Cost of revenue | $928.13M | $928.23M | $754.44M | $715.33M | $631.67M | -0.0% |
| Gross profit | $11.63B | $12.83B | $11.17B | $9.71B | $9.14B | -9.3% |
| Total operating expense | $10.41B | $10.12B | $8.89B | $8.15B | $8.03B | +2.9% |
| Operating income | $1.22B | $2.71B | $2.27B | $1.57B | $1.11B | -54.8% |
| Net interest income | -$1.26B | -$1.48B | -$1.33B | -$1.20B | -$1.14B | +14.7% |
| Pre-tax income | -$327.34M | $817.10M | $826.58M | $58.00M | $1.64B | -140.1% |
| Tax provision | $130.43M | -$359.90M | $134.61M | $17.35M | $536.53M | +136.2% |
| Net income | -$413.26M | $823.54M | $709.52M | $35.99M | $618.52M | -150.2% |
| Net income to common | -$413.26M | $823.54M | $709.52M | $35.99M | $618.52M | -150.2% |
| Basic EPS | -0.31 | 1.06 | 1.15 | 0.10 | 2.05 | -129.2% |
| Diluted EPS | -0.31 | 1.06 | 1.15 | 0.10 | 2.02 | -129.2% |
| EBIT | $936.09M | $2.30B | $2.16B | $1.26B | $2.78B | -59.3% |
| EBITDA | $2.73B | $4.47B | $3.83B | $2.65B | $4.11B | -39.1% |
| Basic shares | 776.49M | 776.92M | 616.97M | 775.50M | 301.72M | -0.1% |
| Diluted shares | 776.49M | 776.92M | 616.97M | 775.50M | 306.20M | -0.1% |
| Line item | 2026-03-31 | 2025-09-30 | 2025-03-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $6.88B | $1.31B | $2.14B | +424.0% |
| Cash & short-term investments | $42.95B | $36.64B | $9.27B | +17.2% |
| Accounts receivable | $4.62B | $4.25B | $4.19B | +8.6% |
| Total current assets | $50.65B | $43.48B | $33.43B | +16.5% |
| Property, plant & equipment | $13.51B | $12.68B | $13.19B | +6.5% |
| Goodwill & intangibles | $31.90B | $30.29B | $29.05B | +5.3% |
| Total assets | $106.49B | $96.43B | $85.26B | +10.4% |
| Total current liabilities | $72.42B | $65.79B | $50.11B | +10.1% |
| Current debt | $48.31B | $43.22B | $34.07B | +11.8% |
| Long-term debt | $1.10B | $1.50B | $6.86B | -26.9% |
| Total debt | $57.17B | $52.55B | $48.79B | +8.8% |
| Total liabilities | $81.04B | $75.11B | $64.82B | +7.9% |
| Retained earnings | — | — | -$12.65B | — |
| Shareholder equity | $20.89B | $17.38B | $7.59B | +20.1% |
| Working capital | -$21.77B | -$22.31B | -$16.68B | +2.4% |
| Net tangible assets | -$11.02B | -$12.90B | -$21.46B | +14.6% |
| Shares issued | 775.99M | 775.50M | 299.99M | +0.1% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders85.56%
Held by institutions0.51%
Institutions holding26
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
283.39
+5.92% from price
SMA 20
288.26
+5.03% from price
SMA 50
266.06
+13.79% from price
SMA 100
273.07
+9.92% from price
SMA 200
254.56
+18.93% from price
EMA 12
289.25
+3.77% from price
EMA 26
283.20
+5.99% from price
EMA 50
275.56
+8.92% from price
RSI (14)
60.1
Neutral
MACD (12,26,9)
6.05
Hist 1.15
ATR (14)
14.95
4.94% of price
Realised vol 30D
54.5%
Annualised
Bollinger upper
313.48
20, 2σ
Bollinger lower
263.05
20, 2σ
50 / 200 cross
Golden
266.06 vs 254.56
Trend bias
Above 200
+18.93%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.42
Less volatile than market
Correlation to SPY
0.10
Largely independent
Realised vol 30D
54.5%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-39.9%
Peak to trough
Max drawdown 5Y
-44.3%
Peak to trough
ATR 14
14.95
4.94% of price
Beta (reported)
0.12
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend dateAug 14, 2007
Next pay date—
Last split10:1
Split dateOct 29, 2010
Headlines
FDA places clinical hold on REGENXBIO’s RGX-121 in MPS II trial
Clinical Trials Arena · 2m ago
Morning Bid: Economic salvos
Reuters · 3m ago
Takeda’s Orzeyful secured Japan MHLW approval for narcolepsy type 1
Hospital Management · 7m ago
SealingTech, a Parsons Corporation company, receives $750 Million Joint Cyber Hunt Kit (JCHK) Full-Rate Production Award from USCYBERCOM
PR Newswire · 9m ago
One in Three U.S. Women Are Already Using AI for Skincare and Bodycare Advice, New Survey Finds
PR Newswire · 9m ago
Innovent Announces 2026 Interim Results and Business Updates
PR Newswire · 9m ago
RBC creates unified Global Transaction Banking business, combining strengths across leading businesses
PR Newswire · 9m ago
Student Storytellers at Boys & Girls Clubs of Twin Cities Take Center Stage at Dream to Screen Awards Powered by Epson, with Special Appearance by Epson Ambassador Shaquille O'Neal
PR Newswire · 9m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.